AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06085625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-Surgery Surveys
Description: After surgery, Participants will complete the same survey as in the pre-surgery visit about 1 day and then 2 weeks after surgery. These surveys will be completed electronically through the MyChart system. They will take about 5-10 minutes to complete and must be done within 24 hours after receiving the survey.~Participants will be monitored for 1 month after your surgery, including your standard-of-care postoperative visit at about 2 weeks. You may be contacted by a provider for a phone or in person visit at the 1-month time point to ask how you are doing.
Study NCT04871919 — intervention group
Intervention type: DRUG
Intervention: Filgotinib
Description: Tablets are administered in accordance with the product label
Study NCT04975230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Self-Management
Description: Intervention delivered by a sleep coach will include 1) initial in-person 50 min consultation; 2) brief 5 min weekly follow ups in a format TBD; and 3) in-person 30 min booster sessions every 3 weeks (total 13 sessions).
Study NCT05887284 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low dose radiotherapy (0.5 Gy)
Description: 12 times 0.5 Gy
Study NCT05887284 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: mock radiation treatment
Description: 6 times 0.0 Gy
Study NCT05887284 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: low dose radiotherapy (1.0 Gy)
Description: 6 times 1.0 Gy
Study NCT06099054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pigtail catheter
Description: Pigtail catheter will be inserted using Seldinger technique under US guidance to drainage exudative pleural effusion by a trained radiologist
Study NCT06099054 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal tube
Description: Chest tube will be inserted according to BTS guideline for insertion of ICT by a trained thoracic surgeon
Study NCT04038203 — intervention group
Intervention type: DEVICE
Intervention: Resonance Raman Spectroscopy (RPS)
Description: RRS is a technology that utilizes vibrational spectroscopy, rather than absorbance spectroscopy, to determine the oxyhemoglobin concentration in tissues. Raman measurements for the UAC neonates will be obtained simultaneously on the right AND left lower extremity for 15 minutes daily in the first week of life.
Study NCT05879172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electric tubular anastomotic device
Description: The electric tubular anastomotic device developed by Suzhou Yingtukang Medical Technology Co., Ltd. is used for colorectal end-to-end and end-to-side anastomosis. This product is suitable for open or minimally invasive colorectal cancer surgery.~Before firing the device, tissue thickness should be carefully assessed to prevent poor staling leading to leakage, inadequate hemostasis, or poor treatment.
Study NCT05879172 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional anastomotic device
Description: Traditional anastomosis is used in this group. Staplers of the same brand are uniformly adopted to avoid differences between groups caused by different brands.
Study NCT05876312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-038
Description: siRNA duplex oligonucleotide
Study NCT05876312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT05128344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMZ002 injectable solution, 0.5mg/mL
Description: Injectable solution
Study NCT05128344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigabatrin, oral
Description: Oral administration
Study NCT05244642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab
Description: A humanized monoclonal immunoglobulin.
Study NCT05244642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's choice of Chemotherapy
Description: Participants will receive one of the following chemotherapies, including but not limited to DHAP (cisplatin 100mg/m2 D1, high dose cytarabine 2 mg/m2 q12h D2, dexamethasone 40mg D1-4, Q3W); ESHAP (etoposide 40 mg/m2 D1-4, cisplatin 25 mg/m2 D1-4, high dose cytarabine 2 mg/m2 D5, methylprednisolone 500mg D1-4, Q3W); DICE (dexamethasone 10mg/m2 D1-4, ifosfamide 1.0g/m2 D1-4, cisplatin 25mg/m2 D1-4, etoposide 60 mg/m2 D1-4, Q3W); ICE (ifosfamide 5 mg/m2 D2, carboplatin AUC 5 D2, etoposide 100 mg/m2 D1-3, Q3W); IGEV (ifosfamide 2 mg/m2 D1-4, gemcitabine 800 mg/m2 D1, D4, vinorelbine 20mg/m2 D1, prednisone 100 mg D1-4, Q3W); GVD (gemcitabine 1g/m2 D1, D8, vinorelbine 20 mg/m2 D1, D8, liposome doxorubicin 15 mg/m2 D1, D8, Q3W); MINE (etoposide 65mg/m2 D1-3, ifosfamide 1.33g/m2 D1-3, mitoxantrone 8mg/m2 d1, Q3W); GemOx (gemcitabine 800mg/m2 D1, D8, oxaliplatin 85mg/m2 D1, Q3W); GemOx (gemcitabine 1000mg/m2 D1, oxaliplatin 100mg/m2d1, Q2W).
Study NCT04353804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment Arm: Computerized Cognitive Rehabilitation
Description: Treatment Arm: Computerized Cognitive Rehabilitation
Study NCT04353804 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control computer games
Description: Active Control computer games
Study NCT05743517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit4Treatment
Description: This study will test the core intervention of an activity tracker and commercially available app (Fitbit) in addition to four components which are expected to improve physical activity. The intervention will be delivered over 12 weeks with a 12 week follow up period.
Study NCT05058495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Lymphedema Self-Care Support Program
Description: The Mobile Lymphedema Self-Care Support Program is composed of three section. First section includes the information about lymphedema and lymphedema self care. Second section includes the exercises videos which women can concurrently exercise with application and an alarm to remind to exercise. Last section is a social network form the women could chat and share anything with eachother. Patients will be told how to use the Mobile Lymphedema Self-Care Support Program and a contact number will be provided to ask questions about the program at any time.
Study NCT06220786 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-level laser therapy
Description: Low-level laser therapy ca. 72 Joules per cm2
Study NCT06220786 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Fake low-level laser therapy
Description: Identical laser pen without production of low-level laser therapy
Study NCT05213052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical cream
Description: Topical cream applied to painful joint or muscle
Study NCT05723393 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: fascial plane injection guided by ultrasound
Study NCT06559917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: life review
Description: After consenting, they will complete the first questionnaire before receiving the Happiness Ledger intervention via social media. Family members will have one week to organize photos, after which patients will share the meaning of the photos. This process will be recorded by the researcher and will last approximately 40 to 60 minutes. The researcher will then create a three-minute video using the photos, and the participating family members will assist in uploading the photos to the family LINE group as feedback to the subjects. The second questionnaire will then be completed.
Study NCT06328829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional Care
Description: Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.
Study NCT06328829 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Care
Description: Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.
Study NCT06328829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oral-esophageal Tube Feeding
Description: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
Study NCT06328829 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric tube
Description: Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
Study NCT06433258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced TSSC curriculum
Description: In addition to the original TSSC curriculum participants will also be educated with the enhanced curriculum which includes components related to alcohol and social determinants of health needs) to promote cancer prevention through healthy lifestyles.
Study NCT06433258 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Original TSSC curriculum
Description: Participants will be educated with evidence-based modules focused on topics such as introduction to TSSC, physical activity, fruit and vegetable consumption, reduce sugar intake, diabetes, portion control, cancer, and high blood pressure.These modules are provided by community health workers who have been trained in the contents of the modules, as well as motivational interviewing techniques for delivering the modules.
Study NCT05058495 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standart lymphedema education
Description: The control group will receive standard lymphedema education. The standard lymphedema education is an online education composed of information about lymphedema and lymphedema self-care.
Study NCT05058495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standart lymphedema education
Description: The control group will receive standard lymphedema education. The standard lymphedema education is an online education composed of information about lymphedema and lymphedema self-care.
Study NCT04855188 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YVOIRE Y-Solution 540
Description: Injection into the deep dermis layer and/or subcutaneous layer in the nasolabial folds based on the randomization assignment.
Study NCT04855188 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: YVOIRE volume plus
Description: Injection into the deep dermis layer and/or subcutaneous layer in the nasolabial folds based on the randomization assignment.
Study NCT04521712 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 2-hour 75-g oral glucose tolerance test and Dexcom G6 Pro continuous glucose monitor
Description: All women enrolled in this study will have a 2-hour 75-g oral glucose tolerance test performed immediately postpartum (within 4 days of delivery), at 4-6 weeks postpartum, and at 6 months postpartum. Enrolled women will also wear a continuous glucose monitor for 10 days at each of these time periods. Both women and their infants will have skin fold thickness measured at each of these 3 study visits to estimate body fat composition. Additionally umbilical cord blood and placental biopsies will be collected at delivery and stored for future research.
Study NCT05623982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNC-038
Description: Administration by intravenous infusion
Study NCT05312554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iris FIT™ PFO closure system
Description: Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Iris Patent foramen ovale occluder according to the INSTRUCTIONS for Use (IFU)
Study NCT05745363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL2846 capsule
Description: AL2846 is a multi-target tyrosine kinase inhibitor
Study NCT04137835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Showmotion
Description: Each healthy volunteers will wear sensors at the interested joint and do the measurement.
Study NCT04890353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate
Description: Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
Study NCT06563297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfentanil
Description: We first start with alfentanil 100 ng/ml, and use the up and down method as adjust 25 ng/ml of concentration of alfentanil each time. An SPI higher than 80 and hyperdynamics (the increased HR and MBP up 20% of baseline or HR>100bpm and ABP>180/100mmHg) indicates insufficient analgesia, therefore increase it by 25 ng/ml at the next patient; an SPI lower than 80 and stable hemodynamics (the changes of HR and MBP within 20% of baseline or HR\<50bpm and ABP\<90/50mmHg) indicates that analgesia is acceptable, and the next patient will decrease it by 25 ng/ml during skull pin fixation. If the analgesia is inadequate, increase alfentanil concentration will be prescribed. On the other hand, if analgesia is adequate, however hyperdynamics was noted, beta blocker or calcium channel blocker will be prescribed. If hypotension (ABP\<90/50 mmHg) or bradycardia (HR\<50 bpm) occur, we first stop alfentanil infusion and treated with ephedrine or atropine, respectively.
Study NCT04640246 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBX-3400
Description: Autologous transfusion
Study NCT04392999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraarticular platelet rich plasma cervical facet injection
Description: Injection of PRP into the cervical facet joints.
Study NCT04392999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: Injection of corticosteroid into the cervical facet joints.
Study NCT06073028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20-minute gait training
Description: All subjects undergo two 20-minute gait trainings using two different kinds of auditory cueing (temporal or spatial), one week apart (D1 and D8).
Study NCT05961813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive intervention for smoking cessation
Description: Patients will be given a brochure and presentation on smoking cessation and will complete 6 visits (2 before surgical intervention, 4 visits within the following 12 months), as well as follow up phone calls for progressi monitorization.
Study NCT05961813 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief intervention for smoking cessation
Description: Patients will be given a brochure and presentation on smoking cessation 4 weeks before surgery, as well as follow up phone calls for progressi monitorization.
Study NCT05502835 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pulse pressure variation
Description: Infusion of 2 ml/kg/hr. Ringer's solution guided by pulse pressure variation.
Study NCT05415397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 400mg
Description: Celecoxib add-on (400mg daily) add-on to treatment as usual (standard antidepressant treatment)
Study NCT05502835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional fluid management
Description: Infusion of 6 ml/kg/hr. Ringer's solution.
Study NCT05415397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo add-on to treatment as usual (standard antidepressant treatment)
Study NCT06580769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Implementation of a physical activity program, executed through immersive virtual reality
Study NCT06040723 — intervention group
Intervention type: DEVICE
Intervention: EndoMind
Description: The EndoMind system is equipped with an AI model for predicting the Hill grade during gastroscopy.
Study NCT05887427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural Mobilisation
Description: Transcutaneous Electrical Stimulation, hotpack, ultrasound and neural mobilization(radial,ulnar,median)
Study NCT05887427 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative physiotherapy
Description: Hotpack,Transcutaneous Electrical Stimulation ,Ultrasound
Study NCT04595370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977
Description: Participants will receive AZD9977 as per the arms they are randomized.
Study NCT05231187 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: T2Resistance Panel
Description: The T2Resistance Panel is an in vitro diagnostic medical device that runs on the T2Dx instrument and detects bacterial markers that are commonly associated with antibiotic resistance. T2Resistance Panel detects thirteen (13) markers of resistance in seven detection channels:~1. blaKPC~2. blaCTX-M~3. blaNDM / blaVIM / blaIMP~4. blaOXA-48 Group~5. vanA / vanB~6. mecA / mecC~7. AmpC (blaCMY / blaDHA)
Study NCT05169710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-4199 CR 200 mg
Description: SEP-4199 CR 200 mg Tablet (supplied in one 200mg tablet and one placebo tablet)
Study NCT05169710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-4199 CR 400 mg
Description: SEP-4199 CR 400 mg tablet (supplied in two 200mg tablets)
Study NCT05169710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet (supplied in two tablets)
Study NCT05846022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: This dry needling study involves bilaterally insertion of a fine sterile needle into upper trapezius muscle fibers using a clean needling technique.
Study NCT05846022 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Needle
Description: Shallow penetration of a solid monofilament needle into the skin alone with the in and out plunging movement of the needle simulated with the needle's guide tube.
Study NCT05635812 — intervention group
Intervention type: OTHER
Intervention: Neuropsychological assessment
Description: neuropsychological assessment and clinical scales duration: 3 hours
Study NCT05635812 — intervention group
Intervention type: OTHER
Intervention: EEG experimentation
Description: duration: 1 hour
Study NCT05635812 — intervention group
Intervention type: OTHER
Intervention: Oculometry experimentation
Description: duration: 30 minutes
Study NCT05138250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 MG
Description: participants will receive 100mg of mepolizumab every 4 weeks for 52 weeks
Study NCT05260957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Induction Phase (Days -42 through -7):~* 1 mg of Mosunetuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Day -42.~* 2 mg of Mosunetuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Day -35.~* 60 mg of Mosunetuzumab administered via intravenous (IV) infusion on (given as per treatment guidelines) on Days -28 and -7.~Consolidation Phase (Day +1 through Day +90): 30 mg IV Mosunetuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Days +14, +35, +56 and +77.
Study NCT05260957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab
Description: Induction Phase (Days -42 through -7): 1.8mg/kg of Polatuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Day -28.~Consolidation Phase (Days +1 through +90): 1.8mg/kg of Polatuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Days +35, +56 and +77.
Study NCT05260957 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T Cell Therapy
Description: Participants will receive CAR-T Cell therapy via infusion on Day 0 (given as per treatment guidelines). Prior to CAR-T Cell Therapy, participants will begin receiving lymphodepleting chemotherapy on Days -5 through -3 (given as per treatment guidelines).
Study NCT05034874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXT-m200
Description: IXT-m200 binds METH with high selectivity and affinity. The product contains a murine METH-binding variable region and the constant domains of a human immunoglobulin G (IgG) 2κ. This antibody isotype was chosen because of the lower risk of immune response compared to an IgG1 or IgG3. IXT-m200 targets METH, does not rely on binding to any endogenous target for its action, and has been well-tolerated in previous clinical studies.